Assembly Bio's (ASMB) HBV Drug Shows Strong Efficacy in Phase 1b Trial

Assembly Biosciences, Inc. (NASDAQ:ASMB) is one of the growth stocks that could double by 2027. On June 25, the company announced positive topline results from its Phase 1b trial of ABI-4334, a capsid assembly modulator for the treatment of chronic hepatitis B.

The 28-day study showed HBV DNA reductions of 2.9 log10 IU/mL at 150 mg and 3.2 log10 IU/mL at 400 mg, with additional declines in HBV RNA. The lower dose achieved saturated inhibition of viral replication, while the higher dose may enhance suppression of cccDNA formation, a key viral reservoir.

The drug was well-tolerated, with no serious adverse events and pharmacokinetics supporting once-daily oral dosing. These results activate a licensing decision for Gilead Sciences, which holds rights to further develop ABI-4334.

Assembly Biosciences, Inc. (NASDAQ:ASMB) is a clinical-stage biotech focused on small-molecule therapies for serious viral infections. Its pipeline includes candidates for hepatitis B, hepatitis delta, herpesviruses, and transplant-related infections. The company collaborates with Gilead Sciences to advance next-generation antiviral treatments.

While we acknowledge the potential of ASMB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: Top 10 Materials Stocks to Buy According to Analysts and 10 Best Organic Food and Farming Stocks to Buy Now.

Disclosure: None. This article is originally published at Insider Monkey.